Measles cases rose 20% last year, driven by a lack of vaccine coverage in the world's poorest countries and those riddled ...

The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...

Regarding hospitalizations among immunocompetent older adults, vaccine effectiveness was 83% for the GSK vaccine and 73% for ...

While Merck's oncology powerhouse Keytruda delivered another multibillion-dollar sales haul in the third quarter, regional ...

Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its investment ...

At the core of this is a recovery for its life science unit, which dipped last year as its boom from components for Covid ...

Although Merck’s vaccine, like Pfizer’s, is approved for use in people at least 18 years of age, Capvaxive is the only pneumococcal disease vaccine that was specifically made to protect adults ...

Several African and ex-Soviet countries have expressed interest in buying Russia's vaccine against smallpox and mpox viruses, ...

Merck reports Q3 sales of $16.7 billion, up 4% year-over-year, with Keytruda revenue rising 17%. EPS beats estimates; 2024 guidance updated on global demand shifts.

Merck's Q3 revenue rises, led by Keytruda's strong 17% YoY growth. Gardasil demand challenges in China impact sales, with ...

But Merck's vaccine that prevents cancer from HPV, the most common sexually transmitted infection in the U.S., posted another quarter of lighter-than-expected sales. But Merck's vaccine that ...